These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27864925)

  • 21. Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma.
    Tsibris H; Lian C; Ho A
    Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What do autoinflammatory syndromes teach about common cutaneous diseases such as pyoderma gangrenosum? A commentary.
    Butler D; Shinkai K
    Dermatol Clin; 2013 Jul; 31(3):427-35. PubMed ID: 23827245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody.
    Dini V; Romanelli M; Bertone M; Talarico S; Bombardieri S; Barachini P
    Int J Low Extrem Wounds; 2007 Jun; 6(2):108-13. PubMed ID: 17558009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment.
    Alavi A; French LE; Davis MD; Brassard A; Kirsner RS
    Am J Clin Dermatol; 2017 Jun; 18(3):355-372. PubMed ID: 28224502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of pyoderma gangrenosum induced by insulin.
    Noronha M; Arora S; Pai K; Sathish Pai B; Jindal A
    Int Wound J; 2019 Oct; 16(5):1239-1242. PubMed ID: 31353778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia.
    Montoto S; Bosch F; Estrach T; Blade J; Nomdedeu B; Nontserrat E
    Leuk Lymphoma; 1998 Jun; 30(1-2):199-202. PubMed ID: 9669691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease.
    Flora A; Kozera E; Frew JW
    Exp Dermatol; 2022 Apr; 31(4):498-515. PubMed ID: 35114021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel murine model of pyoderma gangrenosum reveals that inflammatory skin-gut crosstalk is mediated by IL-1β-primed neutrophils.
    Jatana S; Ponti AK; Johnson EE; Rebert NA; Smith JL; Fulmer CG; Maytin EV; Achkar JP; Fernandez AP; McDonald C
    Front Immunol; 2023; 14():1148893. PubMed ID: 37475852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postoperative Pyoderma Gangrenosum: A Clinical Review of Published Cases.
    Tolkachjov SN; Fahy AS; Cerci FB; Wetter DA; Cha SS; Camilleri MJ
    Mayo Clin Proc; 2016 Sep; 91(9):1267-79. PubMed ID: 27489052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    Yurci A; Guven K; Torun E; Gursoy S; Baskol M; Akgun H; Ozbakir O; Yucesoy M
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):811-5. PubMed ID: 17700270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bromoderma mimicking pyoderma gangrenosum caused by commercial sedatives.
    Oda F; Tohyama M; Murakami A; Kanno K; Sonobe N; Sayama K
    J Dermatol; 2016 May; 43(5):564-6. PubMed ID: 26507105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis).
    Marzano AV; Damiani G; Ceccherini I; Berti E; Gattorno M; Cugno M
    Br J Dermatol; 2017 Jun; 176(6):1588-1598. PubMed ID: 27943240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
    Hubbard VG; Friedmann AC; Goldsmith P
    Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis.
    Rudolph BM; Staib F; Von Stebut E; Hainz M; Grabbe S; Loquai C
    Eur J Dermatol; 2014; 24(2):268-9. PubMed ID: 24721740
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapy Insight: pyoderma gangrenosum-old disease, new management.
    Campbell S; Cripps S; Jewell DP
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):587-94. PubMed ID: 16327838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?
    Adişen E; Oztaş M; Gürer MA
    Dermatology; 2008; 216(2):163-5. PubMed ID: 18216480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1.
    Lu JD; Milakovic M; Ortega-Loayza AG; Marzano AV; Alavi A
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1179-1185. PubMed ID: 32880206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.
    Maronese CA; Pimentel MA; Li MM; Genovese G; Ortega-Loayza AG; Marzano AV
    Am J Clin Dermatol; 2022 Sep; 23(5):615-634. PubMed ID: 35606650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyoderma gangrenosum possibly triggered by adalimumab.
    Kikuchi N; Hiraiwa T; Ohashi T; Hanami Y; Satoh M; Takenoshita H; Yamamoto T
    Eur J Dermatol; 2012; 22(6):804-5. PubMed ID: 23107608
    [No Abstract]   [Full Text] [Related]  

  • 40. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab.
    Groleau PF; Grossberg AL; Gaspari AA
    Cutis; 2015 Jun; 95(6):337-42. PubMed ID: 26125210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.